These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14659654)

  • 1. Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model.
    Sauermann R; Zeitlinger M; Erovic BM; Marsik C; Georgopoulos A; Müller M; Brunner M; Joukhadar C
    Int J Antimicrob Agents; 2003 Dec; 22(6):574-8. PubMed ID: 14659654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis.
    Zeitlinger MA; Erovic BM; Sauermann R; Georgopoulos A; Müller M; Joukhadar C
    J Antimicrob Chemother; 2005 Oct; 56(4):703-8. PubMed ID: 16120628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.
    Tisdale JE; Pasko MT; Mylotte JM
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1500-5. PubMed ID: 2510592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
    Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinico-bacteriological evaluation of the effectiveness of piperacillin in suppurative-inflammatory diseases of the lungs and pleura].
    Skala LZ; Nasonov VN; Nekhorosheva AG; Savitskaia KI; Dutova EN
    Antibiot Khimioter; 1992 Jun; 37(6):27-8. PubMed ID: 1417340
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
    Zelenitsky S; Nash J; Weber Z; Iacovides H; Ariano R
    J Chemother; 2016 Oct; 28(5):390-4. PubMed ID: 27077931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Common pathogens in burn infection and changes in their drug sensitivity].
    Zhang YP
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1991 Jun; 7(2):108-10, 157-8. PubMed ID: 1773380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
    Fish DN; Kiser TH
    Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
    Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
    J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.